Liquidia (NASDAQ:LQDA) Insider Rajeev Saggar Sells 29,534 Shares of Stock

Liquidia Corporation (NASDAQ:LQDA) insider Rajeev Saggar sold 29,534 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $76.84, for a total transaction of $2,269,392.56. Following the completion of the transaction, the insider owned 142,265 shares in the company, valued at approximately $10,931,642.60. This trade represents a 17.19% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Rajeev Saggar also recently made the following trade(s):

• On Wednesday, August 19th, Rajeev Saggar sold 50,000 shares of Liquidia stock. The stock was sold at an average price of $74.06, for a total transaction of $3,703,000.00.
• On Monday, July 13th, Rajeev Saggar sold 9,926 shares of Liquidia stock. The shares were sold at an average price of $71.51, for a total transaction of $709,808.26.

Liquidia Stock Performance

Shares of LQDA stock traded up $1.00 during trading hours on Wednesday, hitting $75.33. The company’s stock had a trading volume of 1,155,908 shares, compared to its average volume of 1,795,268. The stock has a market cap of $6.74 billion, a PE ratio of 54.99 and a beta of 0.58. Liquidia Corporation has a 12-month low of $21.15 and a 12-month high of $93.61. The company has a 50 day moving average of $79.15 and a 200 day moving average of $55.70. The company has a current ratio of 2.31, a quick ratio of 2.12 and a debt-to-equity ratio of 0.63.

Liquidia (NASDAQ:LQDA) last issued its earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.76 by ($0.02). The business had revenue of $171.68 million for the quarter, compared to analysts’ expectations of $168.48 million. Liquidia had a return on equity of 149.65% and a net margin of 30.74%.The company’s revenue for the quarter was up 1842.1% on a year-over-year basis. During the same period last year, the business earned ($0.49) EPS. On average, sell-side analysts forecast that Liquidia Corporation will post 2.57 EPS for the current fiscal year.

Institutional Trading of Liquidia

A number of institutional investors and hedge funds have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Liquidia by 4.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,681 shares of the company’s stock valued at $556,000 after acquiring an additional 1,700 shares during the period. Goldman Sachs Group Inc. grew its position in shares of Liquidia by 10.7% in the first quarter. Goldman Sachs Group Inc. now owns 861,231 shares of the company’s stock valued at $12,703,000 after purchasing an additional 82,955 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Liquidia by 15.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 121,756 shares of the company’s stock worth $1,796,000 after purchasing an additional 16,022 shares in the last quarter. Creative Planning increased its stake in shares of Liquidia by 40.7% during the second quarter. Creative Planning now owns 26,840 shares of the company’s stock worth $334,000 after purchasing an additional 7,765 shares in the last quarter. Finally, Legal & General Group Plc raised its position in shares of Liquidia by 13.4% during the 2nd quarter. Legal & General Group Plc now owns 94,152 shares of the company’s stock worth $1,174,000 after purchasing an additional 11,111 shares during the last quarter. 64.54% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have commented on LQDA shares. Bank of America upped their price objective on Liquidia from $79.00 to $92.00 and gave the stock a “neutral” rating in a research report on Thursday, August 13th. Needham & Company LLC lifted their target price on shares of Liquidia from $70.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. Raymond James Financial reiterated a “strong-buy” rating and issued a $106.00 target price on shares of Liquidia in a research note on Thursday, August 13th. Jefferies Financial Group restated a “buy” rating and set a $60.00 price target on shares of Liquidia in a research report on Monday, May 11th. Finally, Oppenheimer set a $75.00 price target on shares of Liquidia in a research report on Friday, June 5th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $98.08.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).